Funder: American Cancer Society
Due Dates: November 24, 2026 (ACS budget) | December 4, 2026 (CRUK full application)
Funding Amounts: U.S. team: up to $946,000 including indirect costs; UK team: up to £600,000; 1–5 years
Summary: Supports collaborative UK–U.S. research translating biological insights into approaches for primary cancer prevention.
Key Information: Requires independent, full-time faculty leads (or equivalent) at eligible UK and U.S. institutions and CRUK approval before applying.
Description
The American Cancer Society (ACS) and Cancer Research UK (CRUK) jointly support discrete, hypothesis-driven projects that harness biological and mechanistic insights to advance primary cancer prevention. Projects must show how the proposed work and subsequent research could ultimately reduce cancer risk or incidence. Immediate public health impact within the award period is not required.
The partnership seeks genuine, where possible equal, intellectual collaboration between UK and U.S. teams with complementary expertise. Relevant work includes validating prevention targets, developing preventive interventions, modulating precancerous lesions, applying risk stratification, understanding modifiable risk factors, repurposing drugs or dietary compounds, and validating biomarkers or surrogate endpoints. Both exploratory projects with strong conceptual rationale and longer-term studies with robust preliminary data are supported.
